Physician profile
David S Han
NPI 1093755977
$6,773.11
in general payments reported to CMS, 2019-2025
24 companies · $637 in 2025
The $637 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $813 · 2020: $516 · 2021: $1,997 · 2022: $852 · 2023: $921 · 2024: $1,036 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,593.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,487.95 | 2019-2025 | Ozempic, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $1,357.66 | 2020-2021 | |
| Abbott Laboratories | $1,285.32 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $1,141.06 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $473.98 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $292.37 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $132.44 | 2019-2025 | Repatha, Otezla |
| Allergan, INC. | $122.32 | 2020-2021 | |
| Astellas Pharma US INC | $108.26 | 2020-2022 | |
| Pfizer INC. | $98.58 | 2024-2025 | |
| Amarin Pharma, INC. | $84.21 | 2020-2021 | |
| Lilly USA, LLC | $65.95 | 2023-2024 | Mounjaro |
| Kowa Pharmaceuticals America, INC. | $49.65 | 2024-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $41.42 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $31.94 | 2022 |
9 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.